DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
(titres de publication, de périodique et noms de colloque inclus)
2009-01-01 - Article/Dans un journal avec peer-review - Anglais - 4 page(s)

Yamashita J., Yamashita M., Fujie M., Suyama K.A.T., Ito S., Reddy V.K., Yamada M., Ogawa K., Ozaki N., Nakamura S., Aoki T., Yu G., Aoshima K., Kato T., Kamikage N., Kiyofuji K., Takehara Y., Sakahara H., Takayanagi H., Oshikawa T., Laurent Sophie , Burtea Carmen , Vander Elst Luce , Muller Robert , "R&D of novel medicinal materials for curing cancer: sugar modified Gd-DTPA MRI contrast agents and Phospha Sugar Anti-cancer agents" in Journal of Automation, Mobile Robotics & Intelligent Systems, 3, 4, 80-83

  • Codes CREF : Chimie organique (DI1313), Imagerie médicale, radiologie, tomographie (DI3243)
  • Unités de recherche UMONS : Chimie générale, organique et biomédicale (M108)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé), Institut des Biosciences (Biosciences)
  • Centres UMONS : Centre de Recherche en Microscopie et Imagerie Médicale (CMMI)

Abstract(s) :

(Anglais) Novel Sugar Dendritic Gd-DTPA Complexes for MRI Contrast Agents were prepared and evaluated by in vitro and in vivo methods. The sugar dendritic MRI contrast agents have a good blood vesse pool character, and draw blood vessels and liver cancer remarkably clearer than the clinically using Gd-DTPA. Phospha sugar derivatives or phosphorus heterocyclic derivatives provided by functional groups such as epoxide, bromide, etc., were prepared and evaluated by MTT in vitro method. These phospha sugar derivatives showed excellent activities against leukemia cells as well as solid cancer cells in fashions of (i) higher activity, (ii) wider spectra, (iii) higher selectivity and specificity distingushing healthy and cancer cells, etc., compared with the molecular targeting chemotheraputic anti-cancer agent, Gleevec.